BiotechTube

Apixaban

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Heparin-induced Thrombocytopenia

Conditions

Heparin-induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis

Trial Timeline

Dec 18, 2018 → Oct 30, 2019

NCT ID
NCT03594045

About Apixaban

Apixaban is a phase 2 stage product being developed by Bristol Myers Squibb for Heparin-induced Thrombocytopenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT03594045. Target conditions include Heparin-induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis.

What happened to similar drugs?

1 of 1 similar drugs in Heparin-induced Thrombocytopenia were approved

Approved (1) Terminated (0) Active (0)
✅Standard heparin (UFH) versus certoparin (LMWH)NovartisApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (12)

NCT IDPhaseStatus
NCT05187286Pre-clinicalActive
NCT03594045Phase 2Terminated
NCT02958969ApprovedCompleted
NCT03456648Phase 2Completed
NCT02714855Pre-clinicalCompleted
NCT02345343Pre-clinicalCompleted
NCT01885585Pre-clinicalCompleted
NCT02153424Pre-clinicalWithdrawn
NCT02101112Phase 1Completed
NCT01884350ApprovedCompleted
NCT01885598Pre-clinicalCompleted
NCT00252005Phase 2Completed

Competing Products

1 competing product in Heparin-induced Thrombocytopenia

See all competitors
ProductCompanyStageHype Score
Standard heparin (UFH) versus certoparin (LMWH)NovartisApproved
39